- Home
- HCC vs RYTM Comparison
HCC vs RYTM Comparison
Compare HCC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- RYTM
- Stock Information
- Founded
- HCC 2015
- RYTM 2008
- Country
- HCC United States
- RYTM United States
- Employees
- HCC N/A
- RYTM N/A
- Industry
- HCC Coal Mining
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- RYTM Health Care
- Exchange
- HCC Nasdaq
- RYTM Nasdaq
- Market Cap
- HCC 3.4B
- RYTM 3.1B
- IPO Year
- HCC 2017
- RYTM 2017
- Fundamental
- Price
- HCC $69.79
- RYTM $60.08
- Analyst Decision
- HCC Buy
- RYTM Strong Buy
- Analyst Count
- HCC 5
- RYTM 10
- Target Price
- HCC $75.75
- RYTM $62.30
- AVG Volume (30 Days)
- HCC 711.5K
- RYTM 749.5K
- Earning Date
- HCC 10-30-2024
- RYTM 11-05-2024
- Dividend Yield
- HCC 0.46%
- RYTM N/A
- EPS Growth
- HCC N/A
- RYTM N/A
- EPS
- HCC 7.26
- RYTM N/A
- Revenue
- HCC $1,592,759,000.00
- RYTM $112,530,000.00
- Revenue This Year
- HCC N/A
- RYTM $63.64
- Revenue Next Year
- HCC $0.77
- RYTM $42.98
- P/E Ratio
- HCC $9.66
- RYTM N/A
- Revenue Growth
- HCC N/A
- RYTM 81.55
- 52 Week Low
- HCC $50.60
- RYTM $34.17
- 52 Week High
- HCC $75.53
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HCC 54.87
- RYTM 55.15
- Support Level
- HCC $68.92
- RYTM $59.60
- Resistance Level
- HCC $72.00
- RYTM $63.44
- Average True Range (ATR)
- HCC 2.28
- RYTM 2.60
- MACD
- HCC -0.23
- RYTM -0.29
- Stochastic Oscillator
- HCC 48.10
- RYTM 47.67
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.